Last reviewed · How we verify
BioThrax
BioThrax is a marketed drug developed by the Biomedical Advanced Research and Development Authority, primarily indicated for the prevention of anthrax disease. The drug holds a unique position in the market due to its specific indication and the absence of direct competitors. However, the key composition patent is set to expire in 2028, posing a significant risk to revenue sustainability.
At a glance
| Generic name | BioThrax |
|---|---|
| Also known as | Anthrax Vaccine Adsorbed (AVA), Anthrax Vaccine Adsorbed, AVA |
| Sponsor | Biomedical Advanced Research and Development Authority |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Anthrax AV7909 Boost Evaluation Study (PHASE2)
- Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
- Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study (PHASE2)
- NasoShield Study of Safety and Immunogenicity (PHASE1)
- NasoShield in Healthy Adults to Study Safety and Immunogenicity (PHASE1)
- Ciprofloxacin BioThrax Co-Administration Study (PHASE2)
- Anthrax AV7909 Liquid vs Lyophilized (PHASE1)
- Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BioThrax CI brief — competitive landscape report
- BioThrax updates RSS · CI watch RSS
- Biomedical Advanced Research and Development Authority portfolio CI